Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...
Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback